Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Dobutamine differs from dopamine in that:
A. It does not activate peripheral dopaminergic
receptors
B. It does not activate adrenergic β receptors
C. It causes pronounced tachycardia
D. It has good blood-brain barrier penetrability
by

1 Answer

Answer :

A. It does not activate peripheral dopaminergic
receptors
by

Related questions

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Last Answer : Ans: A

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Description : The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Last Answer : B. Dilatation of pupil

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Description : Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Description : In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Last Answer : D. All of the above

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Last Answer : C. For rapid control of certain symptoms while awaiting response to carbimazole

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Which of the following statement(s) is/are true concerning pharmacologic agents used in the treatment of shock? a. The primary difference between dopamine and dobutamine is the absence of significant a adrenergic activity b. The renal and mesenteric vasoconstrictive effects of norepinephrine complicate and sometimes restrict its use c. The apparent paradoxical use of vasodilators, such as nitroprusside, in shock is indicated as a means to augment cardiac function d. Isoproterenol with its potent b-adrenergic effect, is a particularly useful agent in the treatment of all forms of shock

Description : Which of the following statement(s) is/are true concerning pharmacologic agents used in the treatment of shock? a. The primary difference between dopamine and dobutamine is the absence of significant a ... b-adrenergic effect, is a particularly useful agent in the treatment of all forms of shock

Last Answer : Answer: a, b, c Therapeutic adjustments of intravascular volume (preload) and systemic vascular resistance (afterload) form the basis of the treatment strategies for all ... careful constant monitoring of arterial pressure and repeated hemodynamic measurements with a pulmonary artery catheter

The capacity of an antihistaminic to produce sedation depends on the following except (a) Relative affinity for central versus peripheral H1 receptors (b) Ability to penetrate blood-brain barrier (c) Individual susceptibility (d) Ratio of H1 : H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except (a) Relative affinity for central versus peripheral H1 receptors (b) Ability to penetrate blood-brain barrier (c) Individual susceptibility (d) Ratio of H1 : H2 blockade produced by the drug

Last Answer : Ans: D

The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Last Answer : D. Ratio of H1:H2 blockade produced by the drug

The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Last Answer : D. Ratio of H1:H2 blockade produced by the drug

Improvement of memory in Alzheimer's disease is brought about by drugs which increase transmission in (A) cholinergic receptors (B) dopaminergic receptors (C) GABAergic receptors (D) adrenergic receptors

Description : Improvement of memory in Alzheimer's disease is brought about by drugs which increase transmission in (A) cholinergic receptors (B) dopaminergic receptors (C) GABAergic receptors (D) adrenergic receptors

Last Answer : (A) cholinergic receptors

Which of the following adrenergic inhibitors acts directly on the blood vessels, producing vasodilation? a) Prazosin hydrochloride (Minipress) Minipress is a peripheral vasodilator acting directly on the blood vessel. It is not used in angina and coronary artery disease, however, because it induces tachycardia if not preceded by administration of propranolol and a diuretic.

Description : Which of the following adrenergic inhibitors acts directly on the blood vessels, producing vasodilation? a) Prazosin hydrochloride (Minipress) Minipress is a peripheral vasodilator acting ... through centrally mediated alpha-adrenergic stimulation in the brain, producing blood pressure reduction.

Last Answer : a) Prazosin hydrochloride (Minipress) Minipress is a peripheral vasodilator acting directly on the blood vessel. It is not used in angina and coronary artery disease, however, because it induces tachycardia if not preceded by administration of propranolol and a diuretic.

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

Procainamide differs from quinidine in the following respect (a) It does not cause paradoxical tachycardia (b) It has no alfa adrenergic blocking activity (c) It has little antivagal action (d) Both (b) and (c) Ans: D 68. In heart, potassium channels determine (a) Pacemaker function (b) Resting potential (c) Action potential duration (d) All of the above

Description : Procainamide differs from quinidine in the following respect (a) It does not cause paradoxical tachycardia (b) It has no alfa adrenergic blocking activity (c) It has little antivagal action (d) Both (b ... a) Pacemaker function (b) Resting potential (c) Action potential duration (d) All of the above

Last Answer : Ans: D

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Last Answer : D. Both ‘B’ and ‘C’ are correct

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct